Nuvalent reports Q4 net loss $74.8M, cash $1.1B; pivotal data on track for 2025

Nuvalent, Inc.

2024-FY EPS reported -$3.93

Net loss $74.8M (Q4 2024) and $260.8M (FY 2024); cash & equivalents $1.1B, expected to fund into 2028.
Pivotal data for zidesamtinib in TKI pre-treated ROS1+ NSCLC expected H1 2025; NDA submission mid-2025.
Pivotal data for neladalkib in TKI pre-treated ALK+ NSCLC expected year-end 2025; Phase 3 ALKAZAR initiating H1 2025.
Global Expanded Access Programs launched for zidesamtinib and neladalkib for eligible patients.
Appointed Grant Bogle, former Epizyme CEO, to Board of Directors in December 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.